608142-93-4

Basic information

• Product Name: tert-butyl 4-(3-nitropyridin-4-yl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(3-nitropyridin-4-yl)piperazine-1-carboxylate
• CAS NO: 608142-93-4
• Molecular Weight: 308.337
• Mol File: 608142-93-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 447.8±45.0 °C(Predicted)
• Density: 1.258±0.06 g/cm3(Predicted)
• CAS DataBase Reference: tert-butyl 4-(3-nitropyridin-4-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-nitropyridin-4-yl)piperazine-1-carboxylate(608142-93-4)
• EPA Substance Registry System: tert-butyl 4-(3-nitropyridin-4-yl)piperazine-1-carboxylate(608142-93-4)

Safety Data

• Hazardous Substances Data: 608142-93-4(Hazardous Substances Data)

Upstream product

• 13091-23-1 4-chloro-3-nitropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 115812-96-9 4-fluoro-3-nitropyridine 

Downstream Products

• 170017-74-0 1-[1,1-dimethylethoxycarbonyl]-4-(2-aminophenyl)piperazine 
• 1405126-16-0 2-(2,6-difluorophenyl)-N-(4-(1-piperazinyl)-3-pyridinyl)imidazo[1,5-b]pyridazin-7-amine 
• 1405128-82-6 tert-butyl 4-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)-4-pyridinyl)-1-piperazinecarboxylate 
• 1023298-54-5 4-(3-amino-pyridin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 608142-96-7 4-(3-benzenesulfonyl-1H-pyrrolo[3,2-b]pyridin-7-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 608142-95-6 4-(3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridin-7-yl)-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Structure guided optimization, in vitro activity, and in vivo activity of pan-PIM kinase inhibitors

Proviral insertion of Moloney virus (PIM) 1, 2, and 3 kinases are serine/threonine kinases that normally function in survival and proliferation of hematopoietic cells. As high expression of PIM1, 2, and 3 is frequently observed in many human malignancies, including multiple myeloma, non-Hodgkins lymphoma, and myeloid leukemias, there is interest in determining whether selective PIM inhibition can improve outcomes of these human cancers. Herein, we describe our efforts toward this goal. The structure guided optimization of a singleton high throughput screening hit in which the potency against all three PIM isoforms was increased >10,000-fold to yield compounds with pan PIM Kis 10 pM, nanomolar cellular potency, and in vivo activity in an acute myeloid leukemia Pim-dependent tumor model is described.

BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS

The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention related to novel heterocyclic amide compounds of Formula 1: as disclosed herein or a pharmaceutically accept able salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosedare compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease